Treatment-Resistant Depression Risk and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Research base: Moderate.
What is antidepressant treatment resistance?
Treatment-resistant depression (TRD) is broadly defined as a depressive episode that fails to respond adequately to two or more antidepressant trials of adequate dose and duration. It represents a major clinical challenge: approximately one-third of individuals with major depressive disorder do not achieve remission with first-line antidepressant treatment, and a substantial proportion continue to have inadequate responses after multiple trials.
Understanding why some individuals respond well to antidepressants while others do not has both scientific and practical significance. Response variability likely reflects multiple interacting factors: pharmacokinetic differences in drug metabolism, pharmacodynamic differences in receptor biology, heterogeneity in the underlying neurobiology of depression itself, and genetic variation in pathways relevant to neuroplasticity, monoamine signaling, and inflammatory regulation. GWAS of antidepressant response versus treatment resistance attempts to identify the genetic component of this clinical heterogeneity.
The genetics behind antidepressant treatment resistance
Pharmacogenomics GWAS for antidepressant response are methodologically challenging because they require consistent treatment protocols, standardized response assessment, and large sample sizes. As a result, the evidence base remains more limited than for many disease-susceptibility phenotypes. The current dataset reflects a moderate-evidence study with 26 filtered candidate genes.
The top-ranked gene by locus-to-gene scoring is ZNF37A (Zinc Finger Protein 37A, locus-to-gene score 0.763, high confidence). ZNF37A is a KRAB-domain zinc finger protein, a class of transcriptional repressors that regulate large sets of target genes, often in a tissue-specific manner. KRAB-ZFP proteins play roles in gene silencing during development and in regulating retrotransposon activity in the germline. Their expression in neural tissue has been documented, though the specific transcriptional programs regulated by ZNF37A in the context of depression biology or antidepressant pharmacology remain incompletely characterized. The high locus-to-gene score reflects strong positional and regulatory evidence linking this locus to the phenotype.
The remaining ranked genes — ZNF33A (rank 2, low confidence) and ZNF25 (rank 3, low confidence) — are also KRAB-zinc finger family members. The clustering of three ZNF genes at the top of the ranking may reflect a shared genomic locus with multiple candidate genes in linkage disequilibrium rather than independent biological signals from each gene.
Additional candidate genes in the filtered set include ADGRB1 and ADGRB3, both members of the brain-specific angiogenesis inhibitor subfamily of adhesion GPCRs. ADGRB1 (formerly BAI1) is expressed at excitatory synapses and regulates dendritic spine density and glutamatergic transmission, placing it at the synapse biology level relevant to antidepressant mechanisms of action. ADGRB3 (formerly BAI3) regulates dendritic arborization and synaptogenesis in developing neurons. Antidepressants, particularly those that work on monoamine systems, ultimately affect neuroplasticity and synapse remodeling — the biology that ADGRB family proteins help regulate.
MAG (Myelin-Associated Glycoprotein) is also in the filtered set. MAG is produced by oligodendrocytes and is essential for myelination and axon-oligodendrocyte interactions. White matter integrity — which depends on myelin — is consistently altered in neuroimaging studies of treatment-resistant depression. CA10 (Carbonic Anhydrase 10), an atypical carbonic anhydrase without enzymatic activity that is expressed in the brain, and ADTRP (Androgen Dependent TFPI Regulating Protein), which plays roles in angiogenesis and vascular biology, are also among the candidates.
What the research says
The primary genome-wide evidence for antidepressant treatment resistance comes from a dedicated pharmacogenomics study.
Li QS et al. (2020) — Translational Psychiatry — PMID 33106475
"Genome-wide association studies of antidepressant class response and treatment-resistant depression." A GWAS comparing antidepressant class response and treatment-resistant depression, identifying genetic loci that differentiate individuals who respond to standard antidepressant treatment from those who develop treatment-resistant courses. This study examined both class-specific response (SSRIs vs. SNRIs vs. other agents) and the binary TRD phenotype.
Research status: 26 candidate genes filtered from associated loci. ZNF37A is the highest-confidence candidate by locus-to-gene scoring. The evidence is moderate, reflecting the challenges of antidepressant pharmacogenomics GWAS: heterogeneous phenotyping, varied treatment protocols across clinical sites, and sample sizes constrained by the need for longitudinal treatment data.
The moderate confidence tier for this trait reflects a genuine challenge in psychiatric pharmacogenomics: defining and measuring treatment response consistently across large patient populations is difficult. Response criteria vary across studies, and the distinction between treatment-resistant depression and inadequately treated depression (insufficient dose, duration, or adherence) introduces phenotypic noise. Despite these challenges, the Li QS et al. 2020 study represents an important step toward understanding the genetic architecture of antidepressant treatment outcomes.
How antidepressant treatment resistance affects you
Treatment-resistant depression carries substantial burden. Individuals with TRD experience longer depressive episodes, higher rates of psychiatric hospitalization, greater functional impairment, and increased risk of suicidality compared to those who respond to first-line treatment. The progression through multiple failed antidepressant trials is demoralizing and clinically costly.
Current clinical approaches to TRD include augmentation strategies (adding lithium, atypical antipsychotics, or thyroid hormone to antidepressant therapy), switching to a different antidepressant class, adding psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and newer agents like esketamine (Spravato). Understanding genetic predisposition to treatment resistance could eventually help stratify patients toward more aggressive early intervention rather than sequential trial-and-error.
Working with your variant profile
Genetic associations with antidepressant treatment resistance reflect population-level GWAS signals with moderate evidence. This data does not constitute a clinical determination of whether antidepressant therapy will be effective for any individual, and genetic predisposition to treatment resistance is one factor among many — including the specific antidepressant used, dose, duration, comorbid conditions, and psychosocial context.
Treatment decisions for depression should be made in collaboration with a psychiatrist or prescribing clinician, drawing on clinical history, symptom severity, prior treatment response, and emerging pharmacogenomic guidance where available. Validated pharmacogenomic tools for depression treatment exist and are in clinical development, though their routine use is not yet standard of care.
Related traits and genes
Antidepressant treatment resistance is genetically related to major depressive disorder susceptibility, anxiety disorders, neuroticism, and treatment response traits in other psychiatric contexts. The ADGRB1 and ADGRB3 genes connect to synaptogenesis phenotypes; MAG links to white matter integrity and multiple sclerosis genetics. KRAB-ZFP genes like ZNF37A are represented across many GWAS as positional candidates, reflecting their prevalence in the genome rather than established pharmacological roles.
Frequently asked questions
What is ZNF37A and why is it the top gene candidate here?
ZNF37A is a KRAB-domain zinc finger protein, a class of transcriptional repressors that regulate large gene sets in a tissue-specific manner. It is the top-ranked candidate gene by locus-to-gene scoring in the Li QS et al. 2020 study, reflecting strong positional and regulatory evidence at this genomic locus. The specific transcriptional targets of ZNF37A in neurons or antidepressant-relevant pathways are not yet established — it is a genetic candidate requiring functional follow-up rather than a characterized pharmacological target.
How do ADGRB1 and ADGRB3 relate to antidepressant biology?
ADGRB1 and ADGRB3 are adhesion GPCRs expressed in the brain that regulate synaptogenesis, dendritic spine density, and glutamatergic transmission. Antidepressants ultimately work in part by promoting synaptic plasticity and neuroplasticity in circuits affected by depression. These brain-specific synaptic regulatory proteins are biologically plausible candidates in that context, though their direct pharmacological relationship to antidepressant response has not been established.
Why is antidepressant pharmacogenomics still in early stages?
Antidepressant GWAS face several methodological challenges: large sample sizes are needed for adequate power, treatment response must be assessed consistently across diverse clinical settings, and the distinction between biological treatment resistance and inadequate dosing is difficult to capture in retrospective data. These challenges have limited the field relative to disease-risk GWAS of similar sample sizes. The moderate confidence for this trait reflects this current state of the evidence.
Can genetic testing currently predict antidepressant response?
Validated clinical pharmacogenomic panels (such as those testing CYP2D6 and CYP2C19 variants that affect drug metabolism) can inform antidepressant dosing for some medications. The GWAS-derived variants in the Li QS et al. 2020 study are at an earlier stage and are not yet integrated into clinical pharmacogenomic tools. ExomeDNA's GWAS data represents biological context rather than clinical-grade predictive markers.
Is treatment-resistant depression inherited?
Twin studies suggest that a portion of the variation in antidepressant treatment outcomes is heritable, though heritability estimates for this specific trait are more limited than for depression susceptibility itself. The moderate evidence base for TRD genetics reflects early-stage research rather than a conclusion about heritability magnitude. Both genetic and non-genetic factors — including prior treatment history, comorbid conditions, and psychosocial context — contribute to treatment outcomes.